의약품-의료기기 조합 제품 시장 : 제품 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global drug device combination products market is projected to reach USD 379.17 billion by 2030 from USD 243.02 billion in 2025, at a CAGR of 9.3% during the forecast period.

The rapid expansion of the geriatric demographic, coupled with a notable increase in patients suffering from chronic conditions such as diabetes and cardiovascular diseases, is projected to drive the market for drug-device combination products significantly. Additionally, the steady rise in self-administration practices and a heightened emphasis on patient-centric design and adherence to treatment regimens are expected to further propel market growth. Technological advancements in drug-device combination products, the introduction of innovative products, and favorable reimbursement frameworks, along with supportive government policies, are all anticipated to enhance market dynamics. Furthermore, strategic investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of these combination products will likely contribute significantly to market expansion.

The injectable drug delivery devices segment is expected to grow at the highest CAGR during the forecast period.

In the realm of drug-device combination products, injectable drug delivery systems command the largest market share and are experiencing accelerated growth. This trend is predominantly due to their capacity for rapid, targeted administration of complex biologics and other therapies that are unsuitable for oral delivery routes. The escalating prevalence of chronic diseases, such as diabetes and cancer, is a primary driver of demand in this sector. Additionally, the industry is witnessing a paradigm shift towards self-administration facilitated by user-centered designs, including autoinjectors and pen injectors. Continuous innovation in device technology is enhancing patient comfort, safety, and adherence, further propelling market growth.

The autoinjectors subsegment of the injectable drug delivery devices segment captured the largest market share in 2024.

The injectable drug delivery devices can be subcategorized into prefilled syringes, pen injectors, autoinjectors, needle-free injectors, and wearable injectors. Among these, autoinjectors have experienced a pronounced growth trajectory in the market due to their user-friendly design, convenience, and capability to administer accurate doses of medication. These features make autoinjectors particularly suitable for patients with chronic conditions such as diabetes and multiple sclerosis. The architecture of autoinjectors facilitates self-administration, which enhances patient adherence to treatment regimens and minimizes the necessity for frequent visits to healthcare facilities. Given the rising emphasis on home-based care and patient-centric therapeutic solutions, the market for autoinjectors is poised for significant expansion.

North America accounted for the largest market share in 2024.

The global market for drug-device combination products is categorized into five key regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Currently, North America dominates this market due to its substantial burden of chronic diseases, particularly diabetes, which enlarges the patient demographic that relies on these combination products. The region's market growth is further bolstered by the presence of several major industry players and supportive reimbursement policies that facilitate access to innovative therapies. Meanwhile, the Asia Pacific region is projected to experience the highest CAGR during the forecast period, indicating a burgeoning demand and potential for expansion in this sector.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
• By Designation: C-level-30%, Director-level-23%, and Other Designations-47%
• By Region: North America-35%, Europe-20%, Asia Pacific-25%, Latin America-13%, and Middle East & Africa-7%

The major players operating in the drug device combination products market are Abbott (US), Boston Scientific Corporation (US), Medtronic (Ireland), Becton, Dickinson and Company (US), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Sanofi (France), Eli Lilly and Company (US), Merck KGaA (Germany), AbbVie Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Stryker (US), B. Braun SE (Germany), Terumo Corporation (Japan) and Kaleo, Inc.(US).

Research Coverage

This report studies the drug device combination products market based on product type, application, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will allow both established companies and new or smaller firms to understand market trends, helping them to increase their market share. Firms that purchase the report can use one or a combination of the strategies mentioned below to enhance their market presence.

This report provides insights on the following pointers:

• Analysis of Key divers (increasing prevalence of chronic disease, technological advancements in drug device combination products, new product launches & high R&D investment), restraints (stringent regulatory requirement), opportunities (growth in emerging economies, growing adoption of drug device combination products), challenge (lack of training and awareness, and product malfunction & wastage)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the drug device combination products market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the drug device combination products market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the drug device combination products market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key objectives of primary research
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • 2.2.2 MNM REPOSITORY ANALYSIS
  • 2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 DRUG DEVICE COMBINATION PRODUCTS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION AND COUNTRY
• 4.3 DRUG DEVICE COMBINATION PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of chronic diseases
    • 5.2.1.2 Growing adoption of biologics and vaccines
    • 5.2.1.3 High R&D investments from government organizations and private bodies
    • 5.2.1.4 Shift toward personalized medicines and patient-centric care
    • 5.2.1.5 Rising popularity of self-administered medicines
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory policies and compliance hurdles
    • 5.2.2.2 Focus on alternative drug delivery methods
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increased preference for minimally invasive products
    • 5.2.3.2 High growth potential in emerging economies
    • 5.2.3.3 Growing adoption of drug device combination products and expanding biologics market
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Heavy financial impact of drug wastage and device malfunction
    • 5.2.4.2 Lack of standardized reimbursement policies
    • 5.2.4.3 Limited training and education for healthcare professionals
    • 5.2.4.4 Lack of medical specialists and surgeons
• 5.3 INDUSTRY TRENDS
  • 5.3.1 RISING POPULARITY OF SELF-ADMINISTERED MEDICINES AND HOME CARE SETTINGS
  • 5.3.2 INTEGRATION OF DRUG DEVICE COMBINATION PRODUCTS WITH SMART CONNECTED DEVICES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Wearable technologies
    • 5.4.1.2 Drug-eluting technologies
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Connected health and digital technologies
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Advanced materials and biopolymers
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.6.2 KEY BUYING CRITERIA
• 5.7 REGULATORY ANALYSIS
  • 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7.2 REGULATORY FRAMEWORK
    • 5.7.2.1 North America
      • 5.7.2.1.1 US
      • 5.7.2.1.2 Canada
    • 5.7.2.2 Europe
    • 5.7.2.3 Asia Pacific
      • 5.7.2.3.1 India
      • 5.7.2.3.2 China
      • 5.7.2.3.3 Japan
    • 5.7.2.4 Latin America
    • 5.7.2.5 Middle East & Africa
• 5.8 PATENT ANALYSIS
  • 5.8.1 KEY PATENTS GRANTED
• 5.9 TRADE ANALYSIS
  • 5.9.1 TRADE ANALYSIS FOR PREFILLED SYRINGES (HS CODE 300431), 2019-2023
    • 5.9.1.1 Import data for HS Code 300431
    • 5.9.1.2 Export data for HS Code 300431
  • 5.9.2 TRADE DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), 2019-2023
    • 5.9.2.1 Import data for HS Code 300431
    • 5.9.2.2 Export data for HS Code 300431
• 5.10 PRICING ANALYSIS
  • 5.10.1 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024
  • 5.10.2 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY DEVICES, BY KEY PLAYER, 2022-2024
  • 5.10.3 AVERAGE SELLING PRICE TREND OF DRUG DELIVERY COMBINATION PRODUCTS, BY REGION, 2022-2024
    • 5.10.3.1 Average selling price trend for pen injectors, 2022-2024
    • 5.10.3.2 Average selling price trend for inhalers, 2022-2024
    • 5.10.3.3 Average selling price trend for drug-eluting stents, 2022-2024
• 5.11 VALUE CHAIN ANALYSIS
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS
• 5.14 ADJACENT MARKET ANALYSIS
• 5.15 ECOSYSTEM ANALYSIS
  • 5.15.1 ROLE IN ECOSYSTEM
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY
  • 5.16.2 DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION
  • 5.16.3 ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.19 INVESTMENT & FUNDING SCENARIO
• 5.20 REIMBURSEMENT SCENARIO ANALYSIS
• 5.21 CLINICAL PIPELINE ANALYSIS
• 5.22 IMPACT OF AI/GEN AI ON DRUG DEVICE COMBINATION PRODUCTS MARKET
• 5.23 IMPACT OF 2025 US TARIFF ON DRUG DEVICE COMBINATION PRODUCTS MARKET
  • 5.23.1 KEY TARIFF RATES
  • 5.23.2 PRICE IMPACT ANALYSIS
  • 5.23.3 IMPACT ON COUNTRY/REGION
    • 5.23.3.1 North America
      • 5.23.3.1.1 US
    • 5.23.3.2 Europe
    • 5.23.3.3 Asia Pacific
  • 5.23.4 IMPACT ON END-USE INDUSTRIES
    • 5.23.4.1 Hospitals & clinics
    • 5.23.4.2 Ambulatory surgery centers
    • 5.23.4.3 Long-term care facilities
    • 5.23.4.4 Home care settings

6 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE

• 6.1 INTRODUCTION
• 6.2 INJECTABLE DRUG DELIVERY DEVICES
  • 6.2.1 PREFILLED SYRINGES
    • 6.2.1.1 Need to eliminate dosing mistakes and improve patient compliance to drive segment
  • 6.2.2 PEN INJECTORS
    • 6.2.2.1 Ease of self-administration and improved dosage accuracy to fuel adoption
  • 6.2.3 AUTOINJECTORS
    • 6.2.3.1 Ease of use and better patient experience to aid adoption in emergency medical conditions
  • 6.2.4 WEARABLE INJECTORS
    • 6.2.4.1 Rising popularity of embedded wireless devices to propel market growth
  • 6.2.5 NEEDLE-FREE INJECTORS
    • 6.2.5.1 Reduced risk of needlestick injury to fuel market adoption
• 6.3 DRUG-ELUTING STENTS
  • 6.3.1 LOW RATE OF RESTENOSIS TO PROPEL MARKET GROWTH
• 6.4 INHALERS
  • 6.4.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO FUEL UPTAKE
• 6.5 INFUSION PUMPS
  • 6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO FUEL DEMAND FOR AMBULATORY INFUSION PUMPS
• 6.6 TRANSDERMAL PATCHES
  • 6.6.1 RISING INCIDENCE OF CHRONIC DISEASES REQUIRING LONG-TERM MEDICATION TO AID MARKET GROWTH
• 6.7 DRUG-COATED BALLOONS
  • 6.7.1 ABILITY TO DELIVER LOCALIZED DRUG THERAPY WITH MINIMAL SYSTEMIC EXPOSURE TO DRIVE MARKET
• 6.8 OTHER PRODUCT TYPES

7 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 DIABETES MANAGEMENT
  • 7.2.1 HIGH GERIATRIC POPULATION AND INCREASED SEDENTARY LIFESTYLE TO PROPEL MARKET GROWTH
• 7.3 RESPIRATORY DISEASES
  • 7.3.1 RISE IN URBANIZATION, AIR POLLUTION, AND SMOKING TO FUEL RESPIRATORY AILMENTS
• 7.4 OPTHALMOLOGY
  • 7.4.1 RISE OF DIABETIC EYE DISEASES AND FAVORABLE REGULATORY SCENARIO TO AUGMENT MARKET GROWTH
• 7.5 AUTOIMMUNE DISEASES
  • 7.5.1 NEED FOR PROLONGED TREATMENT IN CHRONIC PATIENTS TO SPUR MARKET GROWTH
• 7.6 ONCOLOGY
  • 7.6.1 DRUG DEVICE COMBINATION PRODUCTS TO AID THERAPEUTIC PRECISION AND OPTIMIZE PATIENT OUTCOMES DURING CANCER TREATMENT
• 7.7 INFECTIOUS DISEASES
  • 7.7.1 IRREGULARIZED URBANIZATION AND POOR SANITATION IN EMERGING ECONOMIES TO PROPEL MARKET GROWTH
• 7.8 CARDIOVASCULAR DISEASES
  • 7.8.1 INCREASE IN SEDENTARY LIFESTYLE AND CHANGES IN EATING HABITS TO FUEL MARKET GROWTH
• 7.9 OBESITY MANAGEMENT
  • 7.9.1 INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH
• 7.10 PAIN MANAGEMENT
  • 7.10.1 BETTER PATIENT ADHERENCE AND MINIMAL SIDE EFFECTS TO DRIVE ADOPTION OF TRANSDERMAL PATCHES
• 7.11 OTHER APPLICATIONS

8 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CLINICS
  • 8.2.1 ACCESS TO MULTI-DISCIPLINARY EXPERTISE AND PROCEDURE-BASED CARE TO AID MARKET GROWTH
• 8.3 AMBULATORY SURGERY CENTERS
  • 8.3.1 NEED FOR COST-EFFECTIVE AND HIGH-QUALITY MINIMALLY INVASIVE TREATMENT TO SUPPORT MARKET GROWTH
• 8.4 LONG-TERM CARE FACILITIES
  • 8.4.1 INCREASING INCIDENCE OF CHRONIC DISEASES AMONG ELDERLY AND DISABLED POPULATION TO DRIVE MARKET
• 8.5 HOME CARE SETTINGS
  • 8.5.1 INCREASING DEMAND FOR PATIENT-CENTRIC AND COST-EFFECTIVE HEALTHCARE TO PROPEL MARKET GROWTH
• 8.6 OTHER END USERS

9 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American drug device combination products market during forecast period
  • 9.2.3 CANADA
    • 9.2.3.1 Regulatory modernization and strategic government investments to augment market growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Technological advancements and strong R&D infrastructure to propel market growth
  • 9.3.3 UK
    • 9.3.3.1 Strong emphasis on personalized and value-based healthcare to aid market growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Strong healthcare infrastructure and high investments in biopharmaceutical innovation to boost market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Focus on pharmaceutical-meditech convergence and healthcare modernization to drive market
  • 9.3.6 SPAIN
    • 9.3.6.1 Increasing geriatric population and growing focus on home-based treatment to propel market growth
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Favorable government policies and increased healthcare spending to support market growth
  • 9.4.3 JAPAN
    • 9.4.3.1 Advanced healthcare systems and universal reimbursement policies to spur market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Growing focus on digital health integration and booming biosimilars sector to drive market
  • 9.4.5 SOUTH KOREA
    • 9.4.5.1 Robust R&D infrastructure and enhanced focus on government-industry collaborations to aid market growth
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 Rising healthcare investments by government and private organizations to boost market growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Presence of universal healthcare system and high geriatric population to drive market
  • 9.5.3 MEXICO
    • 9.5.3.1 Focus on nearshoring and improvement in healthcare sector to drive market
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Kingdom of Saudi Arabia
      • 9.6.2.1.1 Developed medical tourism and favorable government initiatives to support market growth
    • 9.6.2.2 UAE
      • 9.6.2.2.1 Increased prevalence of diabetes and focus on innovative patient-centric care to drive market
    • 9.6.2.3 Rest of GCC countries
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.4.1 RANKING OF KEY MARKET PLAYERS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product type footprint
    • 10.5.5.4 Application footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.6.5.1 Detailed list of key startups/SME players
    • 10.6.5.2 Competitive benchmarking of key startups/SME players
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 ABBOTT
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches and approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 ELI LILLY AND COMPANY
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product approvals
      • 11.1.2.3.2 Deals
      • 11.1.2.3.3 Expansions
      • 11.1.2.3.4 Other developments
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 MEDTRONIC
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches and approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 NOVO NORDISK A/S
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches and approvals
      • 11.1.4.3.2 Deals
      • 11.1.4.3.3 Expansions
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 NOVARTIS AG
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product approvals
      • 11.1.5.3.2 Deals
      • 11.1.5.3.3 Expansions
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 SANOFI
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product approvals
      • 11.1.6.3.2 Deals
      • 11.1.6.3.3 Other developments
  • 11.1.7 BOSTON SCIENTIFIC CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product approvals
      • 11.1.7.3.2 Deals
  • 11.1.8 BECTON, DICKINSON AND COMPANY
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
      • 11.1.8.3.2 Other developments
  • 11.1.9 MERCK KGAA
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Deals
  • 11.1.10 ABBVIE INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Product approvals
      • 11.1.10.3.2 Deals
      • 11.1.10.3.3 Expansions
  • 11.1.11 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Product approvals
      • 11.1.11.3.2 Other developments
  • 11.1.12 STRYKER
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 B. BRAUN SE
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
  • 11.1.14 TERUMO CORPORATION
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Product launches and approvals
• 11.2 OTHER PLAYERS
  • 11.2.1 TANDEM DIABETES CARE, INC.
  • 11.2.2 CEQUR SIMPLICITY
  • 11.2.3 INTARCIA THERAPEUTICS, INC.
  • 11.2.4 HALOZYME, INC.
  • 11.2.5 KALEO, INC.
  • 11.2.6 LEAD CHEMICAL CO., LTD.
  • 11.2.7 PURDUE PHARMA L.P.
  • 11.2.8 ALVOGEN
  • 11.2.9 EVOLUTIS
  • 11.2.10 MUNDIPHARMA INTERNATIONAL LIMITED
  • 11.2.11 SPARSHA PHARMA INTERNATIONAL PVT. LTD.
  • 11.2.12 SUPERNUS PHARMACEUTICALS, INC.
  • 11.2.13 ALCON INC.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS